TSHA Stock Overview
A gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Taysha Gene Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.09 |
| 52 Week High | US$3.89 |
| 52 Week Low | US$0.50 |
| Beta | 0.35 |
| 1 Month Change | 36.12% |
| 3 Month Change | 43.72% |
| 1 Year Change | 295.39% |
| 3 Year Change | -86.27% |
| 5 Year Change | n/a |
| Change since IPO | -87.16% |
Recent News & Updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Shareholder Returns
| TSHA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.7% | 2.2% | 1.8% |
| 1Y | 295.4% | 5.8% | 26.1% |
Return vs Industry: TSHA exceeded the US Biotechs industry which returned 6.2% over the past year.
Return vs Market: TSHA exceeded the US Market which returned 26.3% over the past year.
Price Volatility
| TSHA volatility | |
|---|---|
| TSHA Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TSHA's share price has been volatile over the past 3 months.
Volatility Over Time: TSHA's weekly volatility has decreased from 31% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 52 | Sean Nolan | www.tayshagtx.com |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. Fundamentals Summary
| TSHA fundamental statistics | |
|---|---|
| Market cap | US$577.89m |
| Earnings (TTM) | -US$118.00m |
| Revenue (TTM) | US$14.16m |
40.8x
P/S Ratio-4.9x
P/E RatioIs TSHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSHA income statement (TTM) | |
|---|---|
| Revenue | US$14.16m |
| Cost of Revenue | US$0 |
| Gross Profit | US$14.16m |
| Other Expenses | US$132.16m |
| Earnings | -US$118.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -833.60% |
| Debt/Equity Ratio | 75.2% |
How did TSHA perform over the long term?
See historical performance and comparison